{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T10:37:55Z","timestamp":1791715075164,"version":"4.3.4"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Fungal Infect Rep"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1007\/s12281-010-0011-0","type":"journal-article","created":{"date-parts":[[2010,4,12]],"date-time":"2010-04-12T05:14:28Z","timestamp":1271049268000},"page":"96-102","source":"Crossref","is-referenced-by-count":35,"title":["Aerosolized Delivery of Antifungal Agents"],"prefix":"10.1007","volume":"4","author":[{"given":"Jennifer","family":"Le","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daryl S.","family":"Schiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,4,13]]},"reference":[{"key":"11_CR1","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/525258","volume":"46","author":"TJ Walsh","year":"2008","unstructured":"\u2022 Walsh TJ, Anaissie EJ, Denning DW, et al.: Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008, 46:327\u2013360. This general guideline for the management of aspergillosis includes some information on aerosolized antifungal agents.","journal-title":"Clin Infect Dis"},{"key":"11_CR2","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1345\/aph.1G477","volume":"40","author":"RA Mohammad","year":"2006","unstructured":"Mohammad RA, Klein KC: Inhaled amphotericin B for prophylaxis against invasive Aspergillus infections. Ann Pharmacother 2006, 40:2148\u20132154.","journal-title":"Ann Pharmacother"},{"key":"11_CR3","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1097\/01.TP.0000054233.60100.7A","volume":"759","author":"V Monforte","year":"2003","unstructured":"Monforte V, Roman A, Gavalda J, et al.: Nebulized amphotericin B concentration and distribution in the respiratory tract of lung-transplanted patients. Transplantation 2003, 759:1571\u20131574.","journal-title":"Transplantation"},{"key":"11_CR4","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/01.TP.0000101516.08327.A9","volume":"77","author":"RH Drew","year":"2004","unstructured":"Drew RH, Dodds Ashley E, Benjamin DK Jr, et al.: Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation 2004, 77:232\u2013237.","journal-title":"Transplantation"},{"key":"11_CR5","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3109\/10428199209054909","volume":"8","author":"SE Myers","year":"1992","unstructured":"Myers SE, Devine SM, Topper RL, et al.: A pilot study of prophylactic aerosolized amphotericin B in patients at risk for prolonged neutropenia. Leuk Lymphoma 1992, 8:229\u2013233.","journal-title":"Leuk Lymphoma"},{"key":"11_CR6","first-page":"3654","volume":"93","author":"S Schwartz","year":"1999","unstructured":"Schwartz S, Behre G, Heinemann V, et al.: Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial. Blood 1999, 93:3654\u20133661.","journal-title":"Blood"},{"key":"11_CR7","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1086\/313498","volume":"29","author":"JR Wingard","year":"1999","unstructured":"Wingard JR, Kubilis P, Lee L, et al.: Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999, 29:1402\u20131407.","journal-title":"Clin Infect Dis"},{"key":"11_CR8","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/ppul.20594","volume":"42","author":"DE Geller","year":"2007","unstructured":"\u2022 Geller DE, Konstan MW, Smith J, et al.: Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr Pulmonol 2007, 42:307\u2013313. This article offers an excellent review of aerosol delivery systems, including nebulizers.","journal-title":"Pediatr Pulmonol"},{"issue":"3 Pt 2","key":"11_CR9","doi-asserted-by":"crossref","first-page":"71S","DOI":"10.1592\/phco.22.6.71S.33909","volume":"22","author":"P Flume","year":"2002","unstructured":"Flume P, Klepser ME: The rationale for aerosolized antibiotics. Pharmacotherapy 2002, 22(3 Pt 2):71S\u201379S.","journal-title":"Pharmacotherapy"},{"issue":"1","key":"11_CR10","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1183\/09031936.01.00220001","volume":"18","author":"J Boe","year":"2001","unstructured":"Boe J, Dennis JH, O\u2019Driscoll BR, et al.: European Respiratory Society guidelines on the use of nebulizers. Eur Respir J 2001, 18(1):228\u2013242.","journal-title":"Eur Respir J"},{"key":"11_CR11","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1378\/chest.127.1.335","volume":"127","author":"MB Dolovich","year":"2005","unstructured":"Dolovich MB, Ahrens RC, Hess DR, et al.: Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians\/American College of Asthma, Allergy, and Immunology. Chest 2005, 127:335\u2013371.","journal-title":"Chest"},{"issue":"3 Pt 2","key":"11_CR12","doi-asserted-by":"crossref","first-page":"80S","DOI":"10.1592\/phco.22.6.80S.33907","volume":"22","author":"RJ Kuhn","year":"2002","unstructured":"Kuhn RJ: Pharmaceutical considerations in aerosol drug delivery. Pharmacotherapy 2002, 22(3 Pt 2):80S\u201385S.","journal-title":"Pharmacotherapy"},{"key":"11_CR13","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/01376517-200408000-00012","volume":"36","author":"M Bayat","year":"2004","unstructured":"Bayat M, Cook AM: Intrapulmonary administration of medications. J Neurosci Nurs 2004, 36:231\u2013235.","journal-title":"J Neurosci Nurs"},{"issue":"3","key":"11_CR14","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1378\/chest.116.3.775","volume":"116","author":"PW Campbell 3rd","year":"1999","unstructured":"Campbell PW 3rd, Saiman L: Use of aerosolized antibiotics in patients with cystic fibrosis. Chest 1999, 116(3):775\u2013788.","journal-title":"Chest"},{"key":"11_CR15","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1592\/phco.20.3.166.34783","volume":"20","author":"GC Wood","year":"2000","unstructured":"Wood GC, Boucher BA: Aerosolized antimicrobial therapy in acutely ill patients. Pharmacotherapy 2000, 20:166\u2013181.","journal-title":"Pharmacotherapy"},{"key":"11_CR16","doi-asserted-by":"crossref","unstructured":"Hess D, Fisher D, Williams P, et al.: Medication nebulizer performance. Effects of diluent volume, nebulizer flow, and nebulizer brand. Chest 1996, 110:498\u2013505.","DOI":"10.1378\/chest.110.2.498"},{"key":"11_CR17","first-page":"866","volume":"52","author":"R Dhand","year":"2007","unstructured":"Dhand R: The role of aerosolized antimicrobials in the treatment of ventilator-associated pneumonia. Respir Care 2007, 52:866\u2013884.","journal-title":"Respir Care"},{"key":"11_CR18","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1128\/AAC.01449-06","volume":"51","author":"RE Lewis","year":"2007","unstructured":"Lewis RE, Liao G, Hou J, et al.: Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2007, 51:1253\u20131258.","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR19","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1128\/AAC.00315-06","volume":"50","author":"JA Olson","year":"2006","unstructured":"Olson JA, Adler-Moore JP, Schwartz J, et al.: Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model. Antimicrob Agents Chemother 2006, 50:2122\u20132131.","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR20","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/jac\/dkl141","volume":"57","author":"H Vogelsinger","year":"2006","unstructured":"Vogelsinger H, Weiler S, Djanani A, et al.: Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion. J Antimicrob Chemother 2006, 57:1153\u20131160.","journal-title":"J Antimicrob Chemother"},{"key":"11_CR21","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.idc.2006.06.007","volume":"20","author":"D Andes","year":"2006","unstructured":"Andes D: Pharmacokinetics and pharmacodynamics of antifungals. Infect Dis Clin North Am 2006, 20:679\u2013697.","journal-title":"Infect Dis Clin North Am"},{"key":"11_CR22","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1128\/AAC.50.5.1852-1854.2006","volume":"50","author":"EJ Ruijgrok","year":"2006","unstructured":"Ruijgrok EJ, Fens MH, Bakker-Woudenberg IA, et al.: Nebulized amphotericin B combined with intravenous amphotericin B in rats with severe invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2006, 50:1852\u20131854.","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR23","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1183\/09031936.95.08081263","volume":"8","author":"P Diot","year":"1995","unstructured":"Diot P, Rivoire B, Le Pape A, et al.: Deposition of amphotericin B aerosols in pulmonary aspergilloma. Eur Respir J 1995, 8:1263\u20131268.","journal-title":"Eur Respir J"},{"key":"11_CR24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/00000421-199302000-00011","volume":"16","author":"J Gryn","year":"1993","unstructured":"Gryn J, Goldberg J, Johnson E, et al.: The toxicity of daily inhaled amphotericin B. Am J Clin Oncol 1993, 16:43\u201346.","journal-title":"Am J Clin Oncol"},{"key":"11_CR25","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1211\/jpp.57.10.0007","volume":"57","author":"EJ Ruijgrok","year":"2005","unstructured":"Ruijgrok EJ, Fens MH, Bakker-Woudenberg IA, et al.: Nebulization of four commercially available amphotericin B formulations in persistently granulocytopenic rats with invasive pulmonary aspergillosis: evidence for long-term biological activity. J Pharm Pharmacol 2005, 57:1289\u20131295.","journal-title":"J Pharm Pharmacol"},{"key":"11_CR26","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1111\/j.1600-6143.2006.01529.x","volume":"6","author":"TE Corcoran","year":"2006","unstructured":"Corcoran TE, Venkataramanan R, Mihelc KM, et al.: Aerosol deposition of lipid complex amphotericin-B (Abelcet) in lung transplant recipients. Am J Transplant 2006, 6:2765\u20132773.","journal-title":"Am J Transplant"},{"key":"11_CR27","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/BF01739026","volume":"22","author":"J Beyer","year":"1994","unstructured":"Beyer J, Schwartz S, Barzen G, et al.: Use of amphotericin B aerosols for the prevention of pulmonary aspergillosis. Infection 1994, 22:143\u2013148.","journal-title":"Infection"},{"key":"11_CR28","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1128\/AAC.42.7.1597","volume":"42","author":"T Koizumi","year":"1998","unstructured":"Koizumi T, Kubo K, Kaneki T, et al.: Pharmacokinetic evaluation of amphotericin B in lung tissue: lung lymph distribution after intravenous injection and airspace distribution after aerosolization and inhalation of amphotericin B. Antimicrob Agents Chemother 1998, 42:1597\u20131600.","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR29","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1021\/js9604218","volume":"86","author":"MP Lambros","year":"1997","unstructured":"Lambros MP, Bourne DW, Abbas SA, Johnson DL: Disposition of aerosolized liposomal amphotericin B. J Pharm Sci 1997, 86:1066\u20131069.","journal-title":"J Pharm Sci"},{"key":"11_CR30","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1128\/AAC.34.1.29","volume":"34","author":"Y Niki","year":"1990","unstructured":"Niki Y, Bernard EM, Schmitt HJ, et al.: Pharmacokinetics of aerosol amphotericin B in rats. Antimicrob Agents Chemother 1990, 34:29\u201332.","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR31","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.healun.2008.11.004","volume":"28","author":"V Monforte","year":"2009","unstructured":"Monforte V, Ussetti P, Lopez R, et al.: Nebulized liposomal amphotericin B prophylaxis for Aspergillus infection in lung transplantation: pharmacokinetics and safety. J Heart Lung Transplant 2009, 28:170\u2013175.","journal-title":"J Heart Lung Transplant"},{"key":"11_CR32","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ijpharm.2005.02.003","volume":"296","author":"SP Vyas","year":"2005","unstructured":"Vyas SP, Quraishi S, Gupta S, Jaganathan KS: Aerosolized liposome-based delivery of amphotericin B to alveolar macrophages. Int J Pharm 2005, 296:12\u201325.","journal-title":"Int J Pharm"},{"key":"11_CR33","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jinf.2007.01.014","volume":"55","author":"CA Alvarez","year":"2007","unstructured":"Alvarez CA, Wiederhold NP, McConville JT, et al.: Aerosolized nanostructured itraconazole as prophylaxis against invasive pulmonary aspergillosis. J Infect 2007, 55:68\u201374.","journal-title":"J Infect"},{"key":"11_CR34","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1128\/AAC.50.4.1552-1554.2006","volume":"50","author":"BJ Hoeben","year":"2006","unstructured":"Hoeben BJ, Burgess DS, McConville JT, et al.: In vivo efficacy of aerosolized nanostructured itraconazole formulations for prevention of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2006, 50:1552\u20131554.","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR35","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s11095-006-9904-6","volume":"23","author":"JT McConville","year":"2006","unstructured":"McConville JT, Overhoff KA, Sinswat P, et al.: Targeted high lung concentrations of itraconazole using nebulized dispersions in a murine model. Pharm Res 2006, 23:901\u2013911.","journal-title":"Pharm Res"},{"key":"11_CR36","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ejpb.2006.01.006","volume":"63","author":"JM Vaughn","year":"2006","unstructured":"Vaughn JM, McConville JT, Burgess D, et al.: Single dose and multiple dose studies of itraconazole nanoparticles. Eur J Pharm Biopharm 2006, 63:95\u2013102.","journal-title":"Eur J Pharm Biopharm"},{"key":"11_CR37","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1128\/AAC.50.5.1878-1880.2006","volume":"50","author":"B Capitano","year":"2006","unstructured":"Capitano B, Potoski BA, Husain S, et al.: Intrapulmonary penetration of voriconazole in patients receiving an oral prophylactic regimen. Antimicrob Agents Chemother 2006, 50:1878\u20131880.","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR38","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ejpb.2008.12.014","volume":"72","author":"JA Tolman","year":"2009","unstructured":"Tolman JA, Nelson NA, Son YJ, et al.: Characterization and pharmacokinetic analysis of aerosolized aqueous voriconazole solution. Eur J Pharm Biopharm 2009, 72:199\u2013205.","journal-title":"Eur J Pharm Biopharm"},{"key":"11_CR39","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1128\/AAC.39.8.1784","volume":"39","author":"MB Kurtz","year":"1995","unstructured":"Kurtz MB, Bernard EM, Edwards FF, et al.: Aerosol and parenteral pneumocandins are effective in a rat model of pulmonary aspergillosis. Antimicrob Agents Chemother 1995, 39:1784\u20131789.","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR40","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1378\/chest.128.5.3711","volume":"128","author":"A Wong-Beringer","year":"2005","unstructured":"Wong-Beringer A, Lambros MP, Beringer PM, Johnson DL: Suitability of caspofungin for aerosol delivery: physicochemical profiling and nebulizer choice. Chest 2005, 128:3711\u20133716.","journal-title":"Chest"},{"key":"11_CR41","first-page":"10","volume":"39","author":"RA Conte","year":"1996","unstructured":"Conte RA, Kleyman SM, Klein V, et al.: Characterization of a de novo t(Y;9) (q11.2;q22) by FISH technique. Ann Genet 1996, 39:10\u201315.","journal-title":"Ann Genet"},{"key":"11_CR42","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/sj.bmt.1704552","volume":"34","author":"A Safdar","year":"2004","unstructured":"Safdar A, O\u2019Brien S, Kouri IF: Efficacy and feasibility of aerosolized amphotericin B lipid complex therapy in caspofungin breakthrough pulmonary zygomycosis. Bone Marrow Transplant 2004, 34:467\u2013468.","journal-title":"Bone Marrow Transplant"},{"key":"11_CR43","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/BF01726364","volume":"16","author":"Z Erjavec","year":"1997","unstructured":"Erjavec Z, Woolthuis GM, de Vries-Hospers HG, et al.: Tolerance and efficacy of amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in haematological patients. Eur J Clin Microbiol Infect Dis 1997, 16:364\u2013368.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"11_CR44","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/BF01697981","volume":"71","author":"GF Behre","year":"1995","unstructured":"Behre GF, Schwartz S, Lenz K, et al.: Aerosol amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in neutropenic cancer patients. Ann Hematol 1995, 71:287\u2013291.","journal-title":"Ann Hematol"},{"key":"11_CR45","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1399-3062.2006.00125.x","volume":"8","author":"BD Alexander","year":"2006","unstructured":"Alexander BD, Dodds Ashley ES, Addison RM, et al.: Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2006, 8:13\u201320.","journal-title":"Transpl Infect Dis"},{"key":"11_CR46","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1086\/586739","volume":"46","author":"BJ Rijnders","year":"2008","unstructured":"\u2022\u2022 Rijnders BJ, Cornelissen JJ, Slobbe L, et al.: Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis 2008, 46:1401\u20131408. This study of patients with hematologic diseases demonstrated significant reduction in invasive pulmonary aspergillosis with the nebulization of L-AmB. This is the second-largest randomized, placebo-controlled trial of aerosolized amphotericin B products.","journal-title":"Clin Infect Dis"},{"key":"11_CR47","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1053-2498(01)00364-3","volume":"20","author":"V Monforte","year":"2001","unstructured":"Monforte V, Roman A, Gavalda J, et al.: Nebulized amphotericin B prophylaxis for Aspergillus infection in lung transplantation: study of risk factors. J Heart Lung Transplant 2001, 20:1274\u20131281.","journal-title":"J Heart Lung Transplant"},{"key":"11_CR48","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1111\/j.1600-6143.2006.01548.x","volume":"6","author":"S Husain","year":"2006","unstructured":"Husain S, Paterson DL, Studer S, et al.: Voriconazole prophylaxis in lung transplant recipients. Am J Transplant 2006, 6:3008\u20133016.","journal-title":"Am J Transplant"},{"key":"11_CR49","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/00007890-200108150-00036","volume":"72","author":"SM Palmer","year":"2001","unstructured":"Palmer SM, Drew RH, Whitehouse JD, et al.: Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. Transplantation 2001, 72:545\u2013548.","journal-title":"Transplantation"},{"key":"11_CR50","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1016\/j.transproceed.2008.09.020","volume":"40","author":"JM Borro","year":"2008","unstructured":"Borro JM, Sole A, de la Torre M, et al.: Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation. Transplant Proc 2008, 40:3090\u20133093.","journal-title":"Transplant Proc"},{"key":"11_CR51","unstructured":"FDA information for healthcare professionals: Colistimethate. Available at http:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm124894.pdf . Accessed January 26, 2010."},{"key":"11_CR52","unstructured":"GlaxoSmithKline: Important drug warning\u2014Relenza inhalation powder must not be nebulized. Available at http:\/\/www.fda.gov\/downloads\/Safety\/MedWatch\/SafetyInformation\/SafetyAlertsforHumanMedicalProducts\/UCM186224.pdf . Accessed January 26, 2010."},{"key":"11_CR53","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1517\/14740338.6.5.523","volume":"6","author":"SA Knechtel","year":"2007","unstructured":"\u2022\u2022 Knechtel SA, Klepser ME: Safety of aerosolized amphotericin B. Expert Opin Drug Saf 2007, 6:523\u2013532. This article offers an excellent review on the safety of aerosolized amphotericin B.","journal-title":"Expert Opin Drug Saf"},{"key":"11_CR54","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1399-3062.2007.00209.x","volume":"9","author":"CM Lowry","year":"2007","unstructured":"Lowry CM, Marty FM, Vargas SO, et al.: Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: a retrospective study. Transpl Infect Dis 2007, 9:121\u2013125.","journal-title":"Transpl Infect Dis"},{"key":"11_CR55","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.pupt.2008.09.001","volume":"21","author":"L Slobbe","year":"2008","unstructured":"Slobbe L, Boersma E, Rijnders BJ: Tolerability of prophylactic aerosolized liposomal amphotericin-B and impact on pulmonary function: data from a randomized placebo-controlled trial. Pulm Pharmacol Ther 2008, 21:855\u2013859.","journal-title":"Pulm Pharmacol Ther"},{"key":"11_CR56","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1183\/09031936.02.00264002","volume":"20","author":"WH Nikolaizik","year":"2002","unstructured":"Nikolaizik WH, Trociewicz K, Ratjen F: Bronchial reactions to the inhalation of high-dose tobramycin in cystic fibrosis. Eur Respir J 2002, 20:122\u2013126.","journal-title":"Eur Respir J"}],"container-title":["Current Fungal Infection Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s12281-010-0011-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,27]],"date-time":"2019-02-27T22:43:02Z","timestamp":1551307382000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12281-010-0011-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,13]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["11"],"URL":"https:\/\/doi.org\/10.1007\/s12281-010-0011-0","relation":{},"ISSN":["1936-3761","1936-377X"],"issn-type":[{"value":"1936-3761","type":"print"},{"value":"1936-377X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,13]]}}}